POCUSCO: Point Of Care UltraSonography for Risk-stratification of COVID-19 Patients
Study Details
Study Description
Brief Summary
COVID-19 pandemic has developed worldwide in less than 4 months. While most patients have a mild or uncomplicated disease (80%), approximately 15% need hospital care and 5% intensive care. Severe cases are characterized by pulmonary involvement which may progress to acute respiratory distress syndrome (ARDS). Early identification of patients who are likely to get worse is therefore a major issue.
While, chest X-ray has poor diagnostic performances, pulmonary computed tomography (CT scan) seems very sensitive (97%) and quite specific of COVID-19. Sub-pleural bilateral ground-glass pattern can precede the positivity of RT-PCR for SARS-CoV-2. CT scan is now considered as the best imaging test to assess COVID-19 patients and is recommended as first-line diagnosis tool by the French Society of Radiology (SFR). However, performing CT scan in all or many patients with suspected COVID-19 may result in radiology department overload, especially, taking into account bio-cleaning between patients. Moreover, CT scan may lead to adverse effects including induced cancer due to the cumulative diagnostic irradiation.
Chest ultrasonography may be an alternative to CT scan. It is a simple, non-invasive, non-irradiating, inexpensive and available at the point of care (POCUS). Most of emergency physicians and many other specialists (pneumologists, infectious disease or intensive care physicians) are trained to perform chest POCUS and use it in their everyday practice. Multiple studies have demonstrated its superiority to chest X-ray for the detection of pneumonia. In ARDS, a scoring has been developed and has shown good correlation with mortality. POCUS is very effective in detecting peripheral patterns and seems appropriate to explore COVID-19 patients.
Previous studies suggest its interest in SARSCov2 infections for initial patient assessment and identification of lung damage. However, its performances have never been scientifically evaluated to date.
Our main hypothesis is that point of care lung ultrasonography performed during the initial examination may identify high-risk COVID-19 patients.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Patients consulting in the emergeny department of participating centres for suspected or confirmed COVID-19 are checked for inclusion and non-inclusion criteria and asked for study participation.
Including patients have point-of-care lung ultrasonography (POCUS) performed within 48 hours following ED admission. The severity of lung damage is assessed using the lung ultrasonography score on 36 points for ARDS (POCUS score).
Apart POCUS score assessment, patients are managed as usual.
If a chest CT scan is performed, its result is collected and, in particular, the quantification of the extent of pulmonary lesions in percentage from 0 to 100%, carried out according to the recommendations of the French Society of Radiology.
For hospitalized patients, if possible, a second chest ultrasonography is performed on Day 5 +/- 3. The extent of lung damage is assessed by the POCUS score.
A follow-up is carried out on day 14 (D14) and the patient's status according to the "Ordinal Scale for Clinical Improvement" for COVID-19 from WHO is recorded.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Chest Ultrasound Only one arm, all included patients having chest ultrasonography. |
Procedure: Follow-up at 14 days
Point of care chest ultrasonography and 14-day follow-up to assess the evolution of the infection and care requirement (invasive ventilation or death)
|
Outcome Measures
Primary Outcome Measures
- Risk of unfavourable outcome at D14 [14 days]
To assess, in patients with confirmed or probable SARS-CoV-2 infection, chest ultrasonography capacity, using the POCUS score for ARDS, to identify patients with unfavourable outcome at D14. Unfavourable outcome is defined by intubation with mechanical ventilation requirement or death (Stage ≥ 6 on "Ordinal Scale for Clinical Improvement" of the World Health Organization) within 14 days of inclusion. We will determine the 95% confidence interval of the AUC of the ROC curve and consider POCUS capacity as clinically relevant if the lower limit of the 95% confidence interval is at least 0.7.
Secondary Outcome Measures
- Risk of unfavourable outcome over time [14 days]
To evaluate, in patients with a confirmed or probable SARS-CoV-2 infection, whether POCUS score performances vary as a function of time, between D1 and D14, and, if so, until which time horizon its performances are clinically relevant. In this purpose, we will determine the time period for which the lower limit of the 95% confidence interval of the AUC of the POCUS score ROC curve is at least 0.7.
- Risk-stratification threshold values [14 days]
To identify the threshold values of POCUS score to perform risk-stratification in three groups of patients: low-risk patients, intermediate-risk patients, high-risk patients. In this purpose, we will determine two threshold values on the inflection points of the ROC curve: maximizing the specificity for a sensitivity of at least 95%, maximizing the sensitivity for a specificity of at least 95%.
- Adding value of POCUS score to previous risk-stratification clinical rules [14 days]
To study the impact of adding the result of POCUS evaluation to several risk-stratification clinical rules for pulmonary infection or sepsis: qSOFA, CRB 65 and CURB 65 In this purpose, we will attribute 0, 1 or 2 points to POCUS score according to the predefined threshold values and will assess : sensitivities of qSOFA with and without addition of POCUS score result, specificities of qSOFA with and without addition of POCUS score result; sensitivities of CRB 65 with and without addition of POCUS score result, specificities of CRB 65 with and without addition of POCUS score result; sensitivities of CRB 65 with and without addition of POCUS score result, specificities of CRB 65 with and without addition of POCUS score result.
- POCUS score and patient clinical status at D14 [14 days]
To assess, the capacity of POCUS score at D0 to predict patient clinical status at D14 In this purpose, we will determine the correlation coefficient between the POCUS score at D0 and the clinical status of patients at day 14 according to the WHO Ordinal Scale for Clinical Improvement for COVID-19 patients.
- POCUS and CT scan correlation [14 days]
To study the correlation between POCUS and CT scan assessment of lung damage. In this purpose, we will determine the intra-class correlation coefficient between POCUS assessment according to the number of affected areas among 12 and CT scan assessment according to the quantification proposed by the French Society of Radiology: 0 - normal; 1 - minor (< 10%), 2 - moderate (10-25%), 3 - important (25-50%), 4 - severe (50-75%), 5 - critical (> 75%)
- POCUS versus CT scan risk-stratification performances [14 days]
To compare the diagnostic performances of POCUS with that of chest computed tomography to identify patients with unfavourable outcome. In this purpose, we will compare the AUC of the ROC curves of POCUS score and CT scan quantification of lung damage to identify patients with unfavourable outcome (intubation and mechanical ventilation requirement or death)
- POCUS score evolution performances [14 days]
To evaluate, in the subgroup of hospitalized patients having a second chest ultrasonography at Day 5 +/- 3 of inclusion, the performances of the evolution of the POCUS score between the first and the second assessment to identify patients with unfavourable outcome. In this purpose, we will calculate the delta between the first and second POCUS score and determine the AUC of the ROC curve and its 95% confidence interval.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patient with COVID-19 confirmed by positive RT-PCR or considered as probable by the in-charge physician,
-
≥18 years old,
-
Not requiring respiratory assistance and/or other intensive care
-
Not subject to a limitation of active therapeutics
Exclusion Criteria:
-
History of pneumonectomy
-
Any reason making chest ultrasonography impossible
-
Any reason making 14-day follow-up impossible
-
Patient opposition to research participation.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Florence DUPRIEZ | Bruxelles | Belgium | BE 1200 | |
| 2 | MORIN François | Angers | France | 49933 | |
| 3 | COUTURAUD Francis | Brest | France | 29200 | |
| 4 | BAUDIN Laure | Cholet | France | 49325 | |
| 5 | TAZAROURTE Karim | Lyon | France | 69002 | |
| 6 | LE CONTE Philippe | Nantes | France | 44093 | |
| 7 | MARJANOVIC Nicolas | Poitiers | France | 86000 | |
| 8 | SOULAT Louis | Rennes | France | 35033 | |
| 9 | JOLY Luc-Marie | Rouen | France | 76000 | |
| 10 | DELOMAS Thomas | Saint-Lô | France | 50000 | |
| 11 | FLAMENT Thomas | Tours | France | 37044 |
Sponsors and Collaborators
- University Hospital, Angers
Investigators
- Principal Investigator: Philippe LE CONTE, Pr, University Hospital of Nantes
- Principal Investigator: Thomas FLAMENT, Dr, University Hospital of Tours
- Principal Investigator: Louis SOULAT, Pr, University Hospital of Rennes
- Principal Investigator: Nicolas MARJANOVIC, Dr, University Hospital of Poitiers
- Principal Investigator: Francis COUTURAUD, Dr, University Hospital of Brest
- Principal Investigator: Laure BAUDIN, Dr, Hospital of Cholet
- Principal Investigator: Karim TAZAROURTE, Pr, Hospices Civils de Lyon (University Hospital of Lyon)
- Principal Investigator: Thomas DELOMAS, Dr, Hospital of Saint-Lô
- Principal Investigator: Luc-Marie JOLY, Pr, University Hospital, Rouen
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- 2020-A00782-37